Tags

Type your tag names separated by a space and hit enter

The impact of concomitant cytogenetic abnormalities on acute myeloid leukemia with monosomy 7 or deletion 7q after HLA-matched allogeneic stem cell transplantation.
Am J Hematol. 2020 03; 95(3):282-294.AJ

Abstract

Monosomy 7 or deletion 7q (-7/7q-) is the most frequent adverse cytogenetic features reported in acute myeloid leukemia (AML), and is a common indication for allogeneic stem cell transplantation (SCT). Nevertheless, -7/7q- occurs frequently with other high-risk cytogenetic abnormalities such as complex karyotype (CK), monosomal karyotype (MK), monosomy 5 or deletion 5q (-5/5q-), 17p abnormalities (abn(17p)) or inversion of chromosome 3 (inv(3)), the presence of which may influence the outcomes after SCT. A total of 1109 patients were allocated to this study. Two-year probability of leukemia-free survival (LFS) and overall survival (OS) were 30% and 36%, respectively. Two-year probability of non-relapse mortality (NRM) was 20%. We defined five different cytogenetic subgroups: the "-7/7q- ± CK group- designated group1," the "MK group-designated group 2," the "-5/5q- group- designated group 3," the "abn(17p) group- designated group 4" and the "inv(3) group- designated group 5." The 2-year probability of LFS in first remission was 48% for group 1, 36.4% for group 2, 28.4% for group 3, 19.1% for group 4 and 17.3% for group 5, respectively (P < .001). Multivariate analysis confirmed those significant differences across groups. Note, SCT in -7/7q- AML provides durable responses in one third of the patients. The presence of -7/7q- with or without CK in the absence of MK, abn(17p) or inv(3) is associated with a better survival after SCT. On the contrary, addition of MK, -5/5q-, abn(17p) or inv(3) identifies a sub-group of patients with poor prognosis even after SCT.

Authors+Show Affiliations

Section of Hematology, Cliniques Universitaires St-Luc, Brussels, Belgium.Acute Leukemia Working Party of the EBMT. Sorbonne Université, Paris, France. INSERM UMR 938, Paris, France. Service d'Hématologie, Hôpital Saint-Antoine, Paris, France.Acute Leukemia Working Party of the EBMT. Sorbonne Université, Paris, France. INSERM UMR 938, Paris, France. Service d'Hématologie, Hôpital Saint-Antoine, Paris, France.HUCH Comprehensive Cancer Center, Stem Cell Transplantation Unit, Helsinki, Finland.Department of Medicine-Hematology-Oncology, University of Freiburg, Freiburg, Germany.Department of Hematology, Hemostasis, Oncology and Stem Cell Transplantation, Hannover Medical School, Hannover, Germany.Institut Paoli Calmette, Programme de Transplantation & Therapie Cellulaire, Marseille, France.CHU de Lille, LIRIC INSERM U995, Université Lille2, Lille, France.Department of Bone Marrow Transplantation, University Hospital, Essen, Germany.CHU Bordeaux, Hôpital Haut-Leveque, Pessac, France.Nouvel Hôpital Civil, Strasbourg, France.Department of Hematology, Bone Marrow Transplantation, Hôpital Saint-Louis, Paris, France.Division of Hematology, Oncology and Hemostasiology, University Hospital Leipzig, Leipzig, Germany.Service d'Hématologie, Centre Hospitalier Lyon Sud, Lyon, France.University Hospital Gasthuisberg, Leuven, Belgium.Department of Hematology, Erasmus MC Cancer Institute, Rotterdam, The Netherlands.Centre for Clinical Haematology, Queen Elizabeth Hospital, Birmingham, UK.Acute Leukemia Working Party of the EBMT. Sorbonne Université, Paris, France. INSERM UMR 938, Paris, France. Service d'Hématologie, Hôpital Saint-Antoine, Paris, France.Hematology Department, Hospital Clinic, IDIBAPS, Josep Carreras Leukemia Research Institute, Barcelona, Spain.Acute Leukemia Working Party of the EBMT. Chaim Sheba Medical Center, Tel-Hashomer, Israël.

Pub Type(s)

Clinical Trial
Journal Article
Multicenter Study

Language

eng

PubMed ID

31876307

Citation

Poiré, Xavier, et al. "The Impact of Concomitant Cytogenetic Abnormalities On Acute Myeloid Leukemia With Monosomy 7 or Deletion 7q After HLA-matched Allogeneic Stem Cell Transplantation." American Journal of Hematology, vol. 95, no. 3, 2020, pp. 282-294.
Poiré X, Labopin M, Polge E, et al. The impact of concomitant cytogenetic abnormalities on acute myeloid leukemia with monosomy 7 or deletion 7q after HLA-matched allogeneic stem cell transplantation. Am J Hematol. 2020;95(3):282-294.
Poiré, X., Labopin, M., Polge, E., Volin, L., Finke, J., Ganser, A., Blaise, D., Yakoub-Agha, I., Beelen, D., Forcade, E., Lioure, B., Socié, G., Niederwieser, D., Labussière-Wallet, H., Maertens, J., Cornelissen, J., Craddock, C., Mohty, M., Esteve, J., & Nagler, A. (2020). The impact of concomitant cytogenetic abnormalities on acute myeloid leukemia with monosomy 7 or deletion 7q after HLA-matched allogeneic stem cell transplantation. American Journal of Hematology, 95(3), 282-294. https://doi.org/10.1002/ajh.25714
Poiré X, et al. The Impact of Concomitant Cytogenetic Abnormalities On Acute Myeloid Leukemia With Monosomy 7 or Deletion 7q After HLA-matched Allogeneic Stem Cell Transplantation. Am J Hematol. 2020;95(3):282-294. PubMed PMID: 31876307.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - The impact of concomitant cytogenetic abnormalities on acute myeloid leukemia with monosomy 7 or deletion 7q after HLA-matched allogeneic stem cell transplantation. AU - Poiré,Xavier, AU - Labopin,Myriam, AU - Polge,Emmanuelle, AU - Volin,Liisa, AU - Finke,Jürgen, AU - Ganser,Arnold, AU - Blaise,Didier, AU - Yakoub-Agha,Ibrahim, AU - Beelen,Dietrich, AU - Forcade,Edouard, AU - Lioure,Bruno, AU - Socié,Gérard, AU - Niederwieser,Dietger, AU - Labussière-Wallet,Hélène, AU - Maertens,Johan, AU - Cornelissen,Jan, AU - Craddock,Charles, AU - Mohty,Mohamad, AU - Esteve,Jordi, AU - Nagler,Arnon, Y1 - 2020/01/17/ PY - 2019/09/30/received PY - 2019/11/26/revised PY - 2019/12/04/accepted PY - 2019/12/27/pubmed PY - 2020/5/19/medline PY - 2019/12/27/entrez SP - 282 EP - 294 JF - American journal of hematology JO - Am J Hematol VL - 95 IS - 3 N2 - Monosomy 7 or deletion 7q (-7/7q-) is the most frequent adverse cytogenetic features reported in acute myeloid leukemia (AML), and is a common indication for allogeneic stem cell transplantation (SCT). Nevertheless, -7/7q- occurs frequently with other high-risk cytogenetic abnormalities such as complex karyotype (CK), monosomal karyotype (MK), monosomy 5 or deletion 5q (-5/5q-), 17p abnormalities (abn(17p)) or inversion of chromosome 3 (inv(3)), the presence of which may influence the outcomes after SCT. A total of 1109 patients were allocated to this study. Two-year probability of leukemia-free survival (LFS) and overall survival (OS) were 30% and 36%, respectively. Two-year probability of non-relapse mortality (NRM) was 20%. We defined five different cytogenetic subgroups: the "-7/7q- ± CK group- designated group1," the "MK group-designated group 2," the "-5/5q- group- designated group 3," the "abn(17p) group- designated group 4" and the "inv(3) group- designated group 5." The 2-year probability of LFS in first remission was 48% for group 1, 36.4% for group 2, 28.4% for group 3, 19.1% for group 4 and 17.3% for group 5, respectively (P < .001). Multivariate analysis confirmed those significant differences across groups. Note, SCT in -7/7q- AML provides durable responses in one third of the patients. The presence of -7/7q- with or without CK in the absence of MK, abn(17p) or inv(3) is associated with a better survival after SCT. On the contrary, addition of MK, -5/5q-, abn(17p) or inv(3) identifies a sub-group of patients with poor prognosis even after SCT. SN - 1096-8652 UR - https://www.unboundmedicine.com/medline/citation/31876307/The_impact_of_concomitant_cytogenetic_abnormalities_on_acute_myeloid_leukemia_with_monosomy_7_or_deletion_7q_after_HLA_matched_allogeneic_stem_cell_transplantation_ L2 - https://doi.org/10.1002/ajh.25714 DB - PRIME DP - Unbound Medicine ER -